ViennaLab Diagnostics GmbH

Reduce severe side effects of fluoropyrimidine (e.g. 5-FU) treatment by DPYD genotyping.

Fluoropyrimidines are widely used for the treatment of various solid tumors. The PGX-5FU XL StripAssay® covers the four most clinically relevant variants in the dihydropyrimidine dehydrogenase (DPYD) gene with therapeutic relevance for fluoropyrimidine treatment as recommended by the European Medicines Agency in April 2020.

 

PGX-5FU XL

 

  • Fluoropyrimidines (5-Fluorouracil, Capecitabine and Tegafur) are frequently used in cancer therapy. However, some patients develop severe treatment-related toxicity.
  • A part of fluoropyrimidine-related toxicity arises due to impaired activity of the key metabolic enzyme dihydropyrimidine dehydrogenase (DPD) caused by genetic variants in the DPYD gene.
  • CPIC Guidelines recommend DPYD genotype-guided fluoropyrimidine dosing to increase patient safety.

Link to CPIC Guidelines

 

ProductReg. Stat.REFUnit SizeIFUBrochure
PGX-5FU XL StripAssay® CE/IVD4-78020 tests

PDF

PDF

We use Matomo to analyze the access to our website. We pass on information about your use of our website to our partners for analysis. Our partners may combine this information with other data that you have provided to them or that they have collected as part of your use of the services. I agree.

Allow